Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

A rrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said it has signed an asset purchase agreement between Sanofi and a subsidiary of the company, Visirna Therapeutics, which focuses on developing cardiometabolic ...

On just his 100th day as Sanofi's CEO, Paul Hudson has reviewed the business and laid out his vision for the future. | Sanofi spent months hyping its Tuesday investor event, and new CEO Paul ...

Sanofi-Aventis R&D chief Marc Cluzel said last year that his company plans to focus on diabetes, cancer and ophthalmology drugs. Today, the company unveiled two deals that fit with that strategy.

Sanofi CEO offers clues of tomorrow's vision reveal with cancer biotech buy By Eric Sagonowsky Dec 9, 2019 10:25am cancer drugs M&A Paul Hudson Sanofi ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...